Johan Lindberg
Overview
Explore the profile of Johan Lindberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ofverholm I, Lin Y, Mondini J, Hardingz J, Branstrom R, Tsagkozis P, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594770
Background: The etiology of most mesenchymal tumors is unknown, and knowledge about syndromes with an increased risk of tumors in bone or soft tissue is sparse. Methods: We present a...
2.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3381.
PMID: 39198712
No abstract available.
3.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3291-3302.
PMID: 39164518
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline...
4.
Ferrara V, Lindberg J, Wastfelt A
MethodsX
. 2024 May;
12:102753.
PMID: 38808096
The qualitative dimensions of visible features in space can be captured by connecting spatial configurations arranged in a variety of different ways to diverse . By conceptual spaces, we intend...
5.
Ofverholm I, Wallander K, Haglund C, Chellappa V, Wejde J, Gellerbring A, et al.
Clin Cancer Res
. 2024 Apr;
30(12):2647-2658.
PMID: 38573684
Purpose: Tumor classification is a key component in personalized cancer care. For soft-tissue and bone tumors, this classification is currently based primarily on morphology assessment and IHC staining. However, these...
6.
Kiasat A, Prast-Nielsen S, Rautiainen S, Engstrand L, Andersson F, Lindberg J, et al.
Scand J Gastroenterol
. 2024 Mar;
59(6):674-682.
PMID: 38505982
Background: In addition to facilitating lipid digestions, bile acids (BA) are signalling molecules acting on receptors on immune cells and along the gastrointestinal (GI) tract. The aim of this study...
7.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
8.
Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, Ustmert S, et al.
Eur Urol Open Sci
. 2023 Jun;
53:63-66.
PMID: 37292496
Patient Summary: We examined cell-free DNA in blood samples from patients with advanced metastatic prostate cancer who started treatment with lutetium-177-PSMA, a new radioligand therapy. We found that patients with...
9.
Norgaard M, Bjerre M, Fredsoe J, Vang S, Jensen J, De Laere B, et al.
Clin Chem
. 2023 Feb;
69(4):386-398.
PMID: 36762756
Background: Multiple treatments are available for metastatic castration-resistant prostate cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and abiraterone, but therapy resistance remains a major clinical obstacle. We examined...
10.
Renaud G, Norgaard M, Lindberg J, Gronberg H, De Laere B, Jensen J, et al.
Elife
. 2022 Jul;
11.
PMID: 35894300
Sequencing of cell-free DNA (cfDNA) is currently being used to detect cancer by searching both for mutational and non-mutational alterations. Recent work has shown that the length distribution of cfDNA...